Biotech Startups

Prime Discoveries develops multiplex PCR diagnostic panels that detect pathogens and antimicrobial-resistance genes across areas such as respiratory infection, sepsis, gastrointestinal illness, STIs, tropical fevers, and biosurveillance. Its panels serve clinical diagnostics, hospital infection control, public-health surveillance, pharmaceutical QC, and biodefense applications.

4 investors

Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.

4 investors

4 investors

Profluent develops AI foundation models combined with an in-house wet lab to design proteins for applications ranging from human health to industrial uses. It works with partners to author natural and de novo proteins optimized for specific commercial use-cases.

4 investors

Profound Research develops clinical research solutions and decision-support tools for physicians to improve patient access to innovative medical treatments. The company focuses on supporting care delivery decisions that advance medical innovation and patient outcomes.

4 investors

Prolacta Bioscience manufactures 100% human milk-based nutritional products and fortifiers for premature and critically ill infants in hospital neonatal intensive care units. The company's products are used to support nutrition and reduce complications in extremely premature infants globally.

4 investors

Protillion Biosciences develops platform technology for antibody engineering and drug discovery.

4 investors

Psilera is a biotech company developing neuroscience-focused therapeutics, including its lead asset PSIL-006, described as next-generation mindful medicine.

4 investors

Qualio provides a compliance platform for life science companies that combines quality management, regulatory intelligence, and AI agents to accelerate product delivery. The platform helps organizations optimize their quality and compliance systems.

4 investors

Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers. Its pipeline includes clinical and preclinical candidates aimed at KRAS mutations (including G12D and G12V) beyond those addressed by approved G12C inhibitors, alongside a RAS-partner discovery program using conformation-sensitive assays.

4 investors

QUiCKR develops rapid genetic modification quantification kits for cell and gene therapy R&D programs, analyzing structural variants, edits, and genome integrity to accelerate development timelines and reduce costs.

4 investors

Radical Numerics develops AI models and architectures built for biology, including multimodal generative models trained on biological data to support genomic discovery and gene-editing. The company is behind the Evo and Evo 2 generative genomics models and aims to apply AI to biological research and biosecurity, including detection and response to biological threats.

4 investors

RapidPulse Medical is an investor relations page showcasing multiple healthcare-focused investment firms and incubators that back medical device and healthcare technology companies.

4 investors

San Diego biopharmaceutical company developing GPCR-targeted immune-inflammatory drugs; acquired by Celgene for ~$7.2B in 2015.

4 investors

Red Arrow Therapeutics develops cancer therapies using a proprietary nanopolymer drug-delivery system for programmable encapsulation and release of biologics such as peptides, antibodies, and proteins. It aims to build a pipeline of polymer-drug conjugate cancer drugs with targeted tumor delivery and reduced off-tumor toxicity.

4 investors

Red Queen Bio builds an AI-powered biodefense system that rapidly designs and manufactures countermeasures against emerging biological threats, enabling faster defensive responses to evolving pathogenic risks.

4 investors

Software platform to improve drug discovery

4 investors

Refeyn develops mass photometry instruments that measure the mass of individual biomolecules in solution without labels, enabling analysis of protein purity, interactions, and viral vector characterization for research and manufacturing applications.

4 investors

Regeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.

4 investors

REGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies. It operates a late-stage clinical pipeline and manufactures its investigational gene therapies at its facility in Rockville, MD.

4 investors

Relation RX is a biotech company focused on discovering novel medicines through an interdisciplinary approach combining expertise from technology, pharma, academia, and venture.

4 investors

Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders. The company applies precision medicine approaches across oncology and other therapeutic areas.

4 investors

Repair Biotechnologies develops the Cholesterol Degrading Platform, a therapeutic approach for treating conditions caused by localized accumulations of excess cholesterol. Its lead application aims to reduce atherosclerotic plaque in arteries to address cardiovascular diseases such as stroke and heart attack.

4 investors

Replay develops gene therapies for patients with rare genetic diseases. It operates in the biotechnology and gene therapy sector.

4 investors